Familial Adenomatous Polyposis Market Trends Point to Steady Growth Ahead by 2034, DelveInsight Analysis Reveals

DelveInsight's "Familial Adenomatous Polyposis Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Familial Adenomatous Polyposis, historical and forecasted epidemiology as well as the Familial Adenomatous Polyposis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Familial Adenomatous Polyposis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Familial Adenomatous Polyposis Market Forecast
https://www.delveinsight.com/sample-request/familial-adenomatous-polyposis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Familial Adenomatous Polyposis Market Report:
• The Familial Adenomatous Polyposis market size is anticipated to grow with a significant CAGR during the study period (2020-2034).
• In August 2025, Biodexa Pharmaceuticals enrolled the first two participants in its placebo-controlled Phase III Serenta trial, evaluating eRapa, an oral capsule formulation of rapamycin, in patients with familial adenomatous polyposis (FAP). FAP is an inherited disorder that, if untreated, frequently develops into colorectal cancer. The initial enrollments were carried out at the Pan American Center for Oncology Trials in Puerto Rico.
• In March 2025, Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotech focused on developing first-in-class targeted and immune-mediated cancer therapies, announced that the Cancer Prevention Clinical Trials Network has received a "Study May Proceed" letter from the U.S. FDA. This authorization allows the initiation of a Phase 2 clinical trial evaluating TPST-1495, the company's novel dual receptor inhibitor of prostaglandin (PGE2) signaling, for the treatment of patients with Familial Adenomatous Polyposis (FAP).
• In March 2025, Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical-stage biopharmaceutical company focused on developing innovative treatments for diseases with significant unmet needs, has announced the selection of Precision for Medicine, LLC as the clinical research organization (CRO) for the European segment of its upcoming registrational Phase 3 trial of eRapa in Familial Adenomatous Polyposis (FAP). Meanwhile, the U.S. portion of the study will be overseen by LumaBridge, located in San Antonio, Texas. This Phase 3 trial will be a randomized, double-blind, placebo-controlled study involving 168 participants in a 2:1 ratio of eRapa to placebo, conducted across around 30 clinical sites in both the U.S. and Europe.
• In December 2024, Sapience Therapeutics, Inc., a clinical-stage biotech company developing peptide-based treatments targeting cancer-driving oncogenic and immune dysregulation, has announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its candidate ST316 for treating familial adenomatous polyposis (FAP). FAP is a rare, inherited condition characterized by the development of numerous polyps in the colon beginning in adolescence. With no current approved treatments, FAP typically progresses to colorectal cancer (CRC) by age 40 without surgical intervention. FAP is considered a key initiating factor in CRC development, which is projected to affect 150,000 individuals in the U.S. in the coming year.
• Data from Carr et al. (2023) indicates that Familial Adenomatous Polyposis (FAP) affects 1 in 10,000 individuals, making it the second most prevalent inherited colorectal cancer syndrome. Despite its significance, FAP is rare, contributing to only 1% of diagnosed colorectal cancer cases.
• According to the National Organization for Rare Disorders (NORD), Familial adenomatous polyposis affects both males and females equally. It is estimated to occur in approximately one in 5,000 to 10,000 individuals in the United States and contributes to around 0.5% of all cases of colorectal cancer.
• The American Society of Clinical Oncology (ASCO) reports that individuals with FAP face heightened risks of various cancers, including colorectal cancer, desmoid tumor, small bowel cancer, pancreatic cancer, papillary thyroid cancer, hepatoblastoma, stomach cancer, and more.
• Key Familial Adenomatous Polyposis Companies: SLA Pharma, Panbela Therapeutics, Emtora Biosciences, Recursion Pharmaceuticals Inc., Rapamycin Holdings, Recursion Pharmaceuticals, Fog Pharmaceuticals, and others
• Key Familial Adenomatous Polyposis Therapies: Eicosapentaenoic acid free fatty acid (EPA-FFA), Eflornithine (CPP-1X), eRapa, REC-4881, Eicosapentaenoic acid free fatty acid (EPA-FFA), Encapsulated Rapamycin (eRapa), REC-4881, FOG-001, and others
• The Familial Adenomatous Polyposis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Familial Adenomatous Polyposis pipeline products will significantly revolutionize the Familial Adenomatous Polyposis market dynamics.

Familial Adenomatous Polyposis Overview
Familial Adenomatous Polyposis (FAP) is a rare, inherited disorder characterized by the development of hundreds to thousands of adenomatous polyps in the lining of the colon and rectm, typically during the teenage years or early adulthood. These polyps have a high potential to become cancerous if left untreated.

Get a Free sample for the Familial Adenomatous Polyposis Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/familial-adenomatous-polyposis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Familial Adenomatous Polyposis Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Familial Adenomatous Polyposis Epidemiology Segmentation:
The Familial Adenomatous Polyposis market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of Familial Adenomatous Polyposis
• Prevalent Cases of Familial Adenomatous Polyposis by severity
• Gender-specific Prevalence of Familial Adenomatous Polyposis
• Diagnosed Cases of Episodic and Chronic Familial Adenomatous Polyposis

Download the report to understand which factors are driving Familial Adenomatous Polyposis epidemiology trends @ Familial Adenomatous Polyposis Epidemiology Forecast
https://www.delveinsight.com/sample-request/familial-adenomatous-polyposis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Familial Adenomatous Polyposis Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Familial Adenomatous Polyposis market or expected to get launched during the study period. The analysis covers Familial Adenomatous Polyposis market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Familial Adenomatous Polyposis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Familial Adenomatous Polyposis Therapies and Key Companies
• Eicosapentaenoic acid free fatty acid (EPA-FFA): SLA Pharma
• Eflornithine (CPP-1X): Panbela Therapeutics
• eRapa: Emtora Biosciences
• REC-4881: Recursion Pharmaceuticals Inc.
• Eicosapentaenoic acid free fatty acid (EPA-FFA): S.L.A. Pharma AG
• Encapsulated Rapamycin (eRapa): Rapamycin Holdings
• REC-4881: Recursion Pharmaceuticals
• FOG-001: Fog Pharmaceuticals

Discover more about therapies set to grab major Familial Adenomatous Polyposis market share @ Familial Adenomatous Polyposis Treatment Landscape
https://www.delveinsight.com/sample-request/familial-adenomatous-polyposis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Scope of the Familial Adenomatous Polyposis Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Familial Adenomatous Polyposis Companies: SLA Pharma, Panbela Therapeutics, Emtora Biosciences, Recursion Pharmaceuticals Inc., S.L.A. Pharma AG, Rapamycin Holdings, Recursion Pharmaceuticals, Fog Pharmaceuticals, and others
• Key Familial Adenomatous Polyposis Therapies: Eicosapentaenoic acid free fatty acid (EPA-FFA), Eflornithine (CPP-1X), eRapa, REC-4881, Eicosapentaenoic acid free fatty acid (EPA-FFA), Encapsulated Rapamycin (eRapa), REC-4881, FOG-001, and others
• Familial Adenomatous Polyposis Therapeutic Assessment: Familial Adenomatous Polyposis current marketed and Familial Adenomatous Polyposis emerging therapies
• Familial Adenomatous Polyposis Market Dynamics: Familial Adenomatous Polyposis market drivers and Familial Adenomatous Polyposis market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Familial Adenomatous Polyposis Unmet Needs, KOL's views, Analyst's views, Familial Adenomatous Polyposis Market Access and Reimbursement

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
Contact No.: +14699457679
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.